SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Audre Lorde — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientAudre Lorde
Date of birth1934-02-18
IdentifiersMRN HR-ML016-SYN-TD; SSN (made up) 000-16-2937
Document date1979-06-29
AuthorNaomi Fairweather, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month survivorship visit on tamoxifen. [S]

History of Present Illness

Ms. Lorde returns three months after the consultation visit. She has taken tamoxifen daily for eight months. The cooling measures and paced breathing have helped: she now has one or two mild hot flashes a day and is rarely woken at night, so she has not needed venlafaxine. Her periods are regular and lighter, with no bleeding between them. She has had no leg swelling, breathlessness, bone pain, cough, or new lumps, and no swelling or heaviness of the right arm. She walks about 30 minutes most days and has been writing and giving readings. The genetic counseling clinic has offered its first appointment in early October. [S]

ElementDetail
Interval changeHot flashes fewer with non-drug measures
TamoxifenEight months, taken daily
Recurrence symptomsNone
FunctionWalking about 30 minutes most days; writing and giving readings
Genetic counselingFirst available appointment in early October

Review of Systems

SystemResultFinding
ConstitutionalNegativeWeight stable; energy good
EndocrinePositiveOne or two mild hot flashes a day
GenitourinaryNegativeNo abnormal vaginal bleeding
CardiovascularNegativeNo leg swelling or chest pain
MusculoskeletalNegativeNo bone or joint pain
PsychiatricNegativeMood good; PHQ-9 score 3 and GAD-7 score 2

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Tamoxifen 20 mg oral tablet, one tablet by mouth once daily, planned for at least five yearsOne tablet once dailyOral route1978-10-27activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1979-06-29Body height168cmS
1979-06-29Body weight71.6kgS
1979-06-29Body mass index (BMI) [Ratio]25.4kg/m2S
1979-06-29Systolic blood pressure118mm[Hg]S
1979-06-29Diastolic blood pressure74mm[Hg]S
1979-06-29Heart rate70/minS
1979-06-29Respiratory rate14/minS
1979-06-29Body temperature36.7CelS
1979-06-29Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1979-06-29Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
1979-06-29Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]2{score}S

Physical Exam

Vital signs recorded on 1979-06-29; see the Vital Signs section. [S]

SystemFinding
GeneralWell
Breasts and chest wallRight chest wall flat, scar supple, no nodules; left breast without masses
Lymph nodesNo axillary, supraclavicular, or cervical nodes
ExtremitiesArm circumference 29.0 cm on each side; calves soft and non-tender
AbdomenSoft; liver not enlarged

Problems

ProblemClinical statusVerificationCodeProvenance
Invasive ductal carcinoma of the upper outer quadrant of the right breast, stage IA (pT1c pN0(sn) M0), grade 2, estrogen and progesterone receptor positive, HER2 negative, recurrence score 14; treated by right total mastectomy with sentinel node biopsy and on adjuvant tamoxifen; synthetic modern counterpart of the documented 1931 breast cancer and mastectomyactiveconfirmed C50.411S — Synthetic tumor details and treatment; the diagnosis and the mastectomy are documented (D), but no tumor details from her lifetime are used.
Estrogen receptor positive status of the breast cancer (ER 90 percent, PR 60 percent)activeconfirmed Z17.0S — Synthetic receptor result; no receptor status from her lifetime is known.
Absence of the right breast after mastectomy with flat closure; she chose not to have reconstruction and not to wear an external prosthesisactiveconfirmed Z90.11S — Synthetic coding of the documented mastectomy; the decision about a prosthesis echoes her documented choice and is respected as her own.
Long-term use of tamoxifen as adjuvant endocrine therapyactiveconfirmed Z79.810S — Synthetic treatment status.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationCancer-related history and physical examinationEvery 3 to 6 months for the first 3 yearsCompleted todayNo symptoms or signs of recurrence
Medication safetyTamoxifen adherence and side effectsEvery visitCompleted todayTaken daily for eight months
SurveyVasomotor symptom assessmentPeriodically on endocrine therapyCompleted todayOne or two mild hot flashes a day; no medicine needed
ExaminationAbnormal vaginal bleeding inquiry on tamoxifenEvery visitCompleted todayRegular, lighter periods; no intermenstrual bleeding
ExaminationVenous thromboembolism symptom inquiry on tamoxifenEvery visitCompleted todayNo leg swelling, calf pain, or breathlessness
ExaminationLymphedema assessment and risk-reduction counselingEvery visitCompleted todayNo swelling; arm circumferences equal
SurveyDistress, depression, and anxiety screen (PHQ-9 and GAD-7)At periodic intervalsCompleted todayPHQ-9 3 and GAD-7 2, minimal; down from 4 and 3 at intake
SurveyFatigue, cognitive concerns, and sexual or vaginal symptomsAt each visit or periodicallyCompleted todayNone reported
LaboratoryRoutine blood counts, chemistry, liver tests, and tumor markers (CEA, CA 15-3, CA 27.29)Not recommended in asymptomatic stage I to III survivorsNot indicatedNo symptoms to prompt testing; none ordered
ImagingCT, bone scan, PET, or other imaging for distant spreadNot recommended in asymptomatic survivorsNot indicatedNo symptoms; not ordered
ImagingDiagnostic mammogram of the left breastYearly after mastectomyDueBooked for September
ImagingBone density (DXA)Every 2 years on an aromatase inhibitor, on tamoxifen with ovarian suppression, or after chemotherapy-induced menopauseNot indicatedPremenopausal on tamoxifen alone; bone health by diet, vitamin D, and weight-bearing exercise
ReferralGenetic counselingOnceReferredStill on the waiting list three months after the request; first appointment early October. The clinic coordinator was asked to offer any earlier cancellation. No result is needed for her current care
Self-managementHealthy lifestyle counselingEvery visitCompleted todayWalking about 200 minutes a week; strength exercise twice a week started

Goal progress:

Guideline basis: American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)

Follow-up: Left mammogram in September, then a survivorship visit. Genetic counseling in October. Next scheduled visit 1979-09-28: survivorship visit one year after diagnosis, after the yearly mammogram of the left breast. [S]